Full-mouth rehabilitation with dental implants viable option for patients with cognitive and physical disabilities: Study

UK: A 14-year cohort study published in the Journal of Prosthetic Dentistry has found implant-supported prostheses to be effective and that oral rehabilitation under the specified conditions is stable.

The researchers suggest that clinicians should consider this full-mouth rehabilitation with dental implants under general anesthesia (GA) as a viable option for cognitively and physically disabled patients who might traditionally be excluded owing to perceived risks.

Oral rehabilitation with implants is an alternative to the provision of removable dentures in all patients for whom missing teeth require replacement. However, individuals with mental health, cognitive issues, and/or physical disabilities are often excluded from implant-supported prostheses due to the high perceived failure risk linked to poor oral health, systemic conditions, or the presence of parafunction.

Against the above background, Marie-Sophie Bogner, Guy´s & St Thomas´ NHS Foundation Trust, London, United Kingdom, and colleagues aimed to describe the outcomes, protocols, and survival rates of oral rehabilitation with implant-supported prostheses in patients with physical and cognitive disabilities treated under GA in a French unit of Special Care Dentistry.

For this purpose, the researchers conducted a retrospective cohort study on patient files. Data included demographics and information about the prosthetic and surgical phases of rehabilitation. Radiological and clinical reports were retrieved to establish the success, survival, and failure rates of implant placement as per the Health Scale for Dental Implants (HDSI) classification.

Two hundred ninety-eight dental implants had been placed under general anesthesia in 57 patients between 2007 and 2021.

The researchers reported the following findings:

  • The prevalence of technical and biological postoperative complications was 14% and 13%, respectively.
  • Thirty implants were determined to be failures.
  • The estimated survival time in the population studied for loaded implants was 144.7 months.
  • The cumulative survival rate was estimated to be 86% at 157 months.

To conclude, the study found implant-supported prostheses to be effective and that oral rehabilitation carried out under the conditions described was determined to be stable.

Reference:

Bogner MS, Chambas V, Veyrune JL, Faulks D, Hennequin M. Oral implant rehabilitation under general anesthesia for patients with cognitive and physical disabilities: A 14-year cohort study. J Prosthet Dent. 2024 Jan 30:S0022-3913(24)00012-X. doi: 10.1016/j.prosdent.2024.01.012. Epub ahead of print. PMID: 38296761.

Powered by WPeMatico

Mazdutide Shows Promise in Controlling blood sugar and Obesity in Diabetes Patients: Study

Mazdutide, a dual agonist drug was found to target weight reduction and additionally to manage blood glucose levels in individuals with overweight and obesity. The key highlights of this study was published in the recent edition of Frontiers in Endocrinology.

Amidst the anticipation surrounding the efficacy of Mazdutide, the concerns regarding the scarcity of comprehensive evidence on its effectiveness and safety prevailed. To address this, a recent study by David Lubasi Nalisa and coulleagues was conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the impact of Mazdutide on weight reduction among adults with and without diabetes.

Analysis of seven RCTs involving a total of 680 participants revealed the superiority of Mazdutide over placebo in various aspects. The drug showed effectiveness in reducing body weight, systolic and diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein.

Mazdutide demonstrated positive effects in the management of hemoglobin A1c (HbA1c) and fasting plasma glucose levels in individuals with type 2 diabetes which underlines its potential as a multifaceted therapeutic approach.

Further analysis through subgroup and meta-regression analyses unveiled nuances, where weight reduction was notable and more significant in non-diabetic individuals when compared to the diabetics, especially among the individuals who were undergoing longer treatment durations (24 weeks).

The outcomes of this study also highlighted a pertinent concern regarding the safety profile of Mazdutide. While the drug expressed promising efficacy, the participants reported transient mild to moderate gastrointestinal side effects which suggests a need for careful monitoring and management strategies.

Reference:

Nalisa, D. L., Cuboia, N., Dyab, E., Jackson, I. L., Felix, H. J., Shoki, P., Mubiana, M., Oyedeji-Amusa, M., Azevedo, L., & Jiang, H. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. In Frontiers in Endocrinology (Vol. 15). Frontiers Media SA. https://doi.org/10.3389/fendo.2024.1309118

Powered by WPeMatico

P2Y12 inhibitor monotherapy after 3 months of DAPT noninferior to 12 months of DAPT after PCI: JAMA

South Korea: P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) is not inferior to 12-month DAPT in patients with coronary artery disease undergoing PCI with the latest generation of drug-eluting stents, findings from SHARE Randomized Clinical Trial have shown. The findings were published online in JAMA Network Open on March 7, 2024.

The randomized clinical trial of 1387 patients in South Korea revealed the net adverse clinical events (NACEs) rate to be 1.7% for the P2Y12 inhibitor monotherapy group and 2.6% for the DAPT group. The 1-sided confidence limit of this difference was within the noninferiority margin of 3.0%.

P2Y12 inhibitor monotherapy after DAPT (a P2Y12 inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for patients undergoing percutaneous coronary intervention (PCI) with a drug-eluting stent. Pil-Ki Min, Yonsei University College of Medicine, Seoul, Republic of Korea, and colleagues aimed to investigate whether P2Y12 inhibitor monotherapy following three months of DAPT was noninferior to 12 months of DAPT following PCI with a drug-eluting stent.

For this purpose, the researchers conducted the SHARE open-label, noninferiority randomized clinical trial from 2017 to 2020. Final 1-year clinical follow-up completed in 2022. The study was a multicenter trial conducted at 20 hospitals in South Korea. It enrolled patients who underwent successful PCI with bioabsorbable polymer everolimus-eluting stents.

The participants were randomly assigned to receive P2Y12 inhibitor monotherapy after 3 months of DAPT (n = 694) or 12 months of DAPT (n = 693).

The primary outcome was a net adverse clinical event, a composite of major bleeding and major adverse cardiac and cerebrovascular events (myocardial infarction, cardiac death, stroke, stent thrombosis, or ischemia-driven target lesion revascularization) between 3 and 12 months after the index PCI. The major secondary outcomes were MACCEs and major bleeding. The noninferiority margin was 3.0%.

The researchers reported the following findings:

  • Of the total 1452 eligible patients, 65 patients were excluded before the 3-month follow-up, and 1387 patients (mean age, 63.0 years; 76.1% men) were assigned to P2Y12 inhibitor monotherapy (n = 694) or DAPT (n = 693).
  • Between 3 and 12 months of follow-up, the primary outcome (using Kaplan-Meier estimates) occurred in 1.7% of patients in the P2Y12 inhibitor monotherapy group and 2.6% of patients in the DAPT group.
  • For the major secondary outcomes (using Kaplan-Meier estimates), major adverse cardiac and cerebrovascular events occurred in 1.5% of patients in the P2Y12 inhibitor monotherapy group and 2.0% of patients in the DAPT group.
  • Major bleeding occurred in 1 patient in the P2Y12 inhibitor monotherapy group and five patients in the DAPT group.

“These findings suggest that early discontinuation of aspirin and P2Y12 monotherapy was not inferior to 12 months of DAPT,” the researchers wrote.

“Further research is required to analyze the impact of this strategy on individual outcomes, including bleeding events,” they concluded.

Reference:

Min P, Kang TS, Cho Y, et al. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial. JAMA Netw Open. 2024;7(3):e240877. doi:10.1001/jamanetworkopen.2024.0877

Powered by WPeMatico

KDIGO 2024 Guideline for ANCA Vasculitis management aims to improve care

USA: An article published in Kidney International reports a new guideline from Kidney Disease: Improving Global Outcomes (KDIGO) that provides updated recommendations on the management of antineutrophilic cytoplasmic antibody (ANCA)–-associated vasculitis (AAV).

The updated guideline addresses key recent developments, the recent regulatory approval of the C5a receptor inhibitor avacopan as an add-on therapy to the standard of care.

The recommendation offers guidance on avacopan use as an alternative to glucocorticoids, while also addressing new evidence on using lower doses of corticosteroids. Further recommendations address therapies, including plasma exchange for use in patients with advanced kidney disease.

“The ANCA Vasculitis Guideline includes significant updates aimed at enhancing clinical decision-making, integrating new treatments with established clinical practices,” Co-chair Jurgen Floege, MD, senior professor in the Division of Nephrology and Immunology at the University of Aachen, Aachen, Germany, said, in a press statement.

“We anticipate that the comprehensive research, clinical perspectives, and collaborative expertise reflected in this guideline will contribute to better outcomes for individuals grappling with this complex condition,” he said.

Co-chair Brad Rovin, MD, the Lee A. Hebert Professor of Nephrology at The Ohio State University Wexner Medical Center, Columbus, Ohio, added that “we are excited to release the KDIGO 2024 ANCA Vasculitis Guideline, which offers new guidance for managing the intricacies of ANCA vasculitis treatment, particularly with the emergence of innovative therapies.”

In 2021, KDIGO published Clinical Practice Guidelines for Glomerular Diseases that summarized recommendations for 11 diseases based on all available evidence through June 2020. The new recommendations are based on the latest evidence from randomized controlled trials, published since July 2022.

Recommendations are based on a systematic review of the evidence and are graded for the strength of the recommendation and the certainty of the evidence. Practice points were issued when there had not been a systematic review. The practice points were ungraded, consensus-based statements representing the judgement of the KDIGO Work Group.

The following are the key takeaways from the guideline:

  • According to the executive summary, the most important update relates to induction therapy, with a recommendation for a more rapid reduction of the glucocorticoid dose when used in combination with cyclophosphamide or rituximab in the initial treatment of new-onset AAV.
  • Further evidence shows greater recovery of low glomerular filtration rate (GFR) with avacopan compared with glucocorticoid therapy.
  • The guideline notes that data show patients most likely to benefit from avacopan are those with an increased risk for glucocorticoid toxicity.
  • The guideline recommends against the routine use of plasma exchange for patients presenting with a GFR < 50 mL/min/1.73 m2, but it can be considered in patients with more severe presentations, or with alveolar haemorrhage and hypoxemia, who have high mortality rates.
  • Plasma exchange is recommended for patients with concomitant anti–glomerular basement membrane disease.
  • Plasma exchange is not required for the therapy of diffuse alveolar haemorrhage in the absence of hypoxemia.
  • The guideline also has no new clinical recommendations for AAV patients who have relapsing or refractory disease or who have had kidney transplantation.
  • No major changes have been made in recommendations regarding diagnosis and assessment of the prognosis of AAV or regarding maintenance therapy.

Randomized controlled trials were prioritized as the primary source of evidence. “In the development of these guidelines, no scoping exercise with patients, limited searches of the qualitative literature, or formal qualitative evidence synthesis examining patient priorities and experiences were undertaken,” the authors noted.

“While resources were considered in developing the recommendations, “formal economic evaluations were not undertaken for all topics.”

Reference:

Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis. Kidney Int. 2024;105(3S):S71–S116.

Powered by WPeMatico

Rapid syndromic PCR tests tied to more targeted antibiotic treatment for pneumonia: JAMA

Researchers have found in a new randomized trial that rapid syndromic PCR tests could complement or replace culture-based diagnostic methods for pneumonia.

Lower respiratory tract infections, including CAP (community-acquired pneumonia), cause hospital admissions and mortality. Molecular tests can potentially optimize treatment decisions and CAP management, but limited evidence exists to support their routine use.
According to an original investigation on Infectious Diseases published on March 6, 2024, in JAMA Network Open, researchers concluded that PCR testing for lower respiratory tract pathogens could provide faster, more targeted treatment for patients with suspected CAP, suggesting it could be some standard, time-consuming diagnostic tests. This study included 374 patients and found that molecular testing led to more CAP-suspected patients receiving pathogen-directed treatment, with a median time to pathogen-directed treatment reduced by 9.4 hours compared to standard care.
Adults with suspected community-acquired pneumonia were enrolled in the study and randomly assigned to either the intervention or standard-of-care group. The study’s primary outcomes included the provision of pathogen-directed treatment based on a microbiological test result and the time to provision of pathogen-directed treatment.
Key findings from the study are:
  • The study had 221 men and 153 women with a median age of 72 years.
  • Sixty-six patients in the intervention arm and 25 in the standard-of-care arm received pathogen-directed treatment.
  • The intervention group was superior to the standard of care for the proportion of participants who received pathogen-directed treatment and time to pathogen-directed treatment.
  • The odds ratio for the provision of pathogen-directed treatment was 3.53.
  • The mean difference in time to pathogen-directed treatment was −9.4 hours.
  • The hazard ratio for intervention was 3.08 compared with the standard of care
Concluding further, they said that routine deployment of PCR testing for LRT pathogens led to faster and more targeted microbial treatment for suspected CAP patients. They added that rapid molecular testing could complement or replace selected standard, time-consuming, laboratory-based diagnostics.
Reference:
Markussen DL, Serigstad S, Ritz C, et al. Diagnostic Stewardship in Community-Acquired Pneumonia With Syndromic Molecular Testing: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(3):e240830. doi:10.1001/jamanetworkopen.2024.0830

Powered by WPeMatico

Unsuccessful Angioplasty: Cardiologist, Hospital slapped Rs 2 lakh compensation

Hoshiarpur: The District Consumer Disputes Redressal Commission, Hoshiarpur, recently slapped Rs 2 lakh compensation on a private hospital and its Cardiologist for an unsuccessful Coronary Percutaneous Old Balloon Angioplasty procedure on a patient.

Observing that the doctor had not been vigilant while performing the procedure, the Commission noted, “…we conclude/ deduce that the OP 1 and the OP2 have caused an unintentional loss to the complainant through lack of care, caution and vigilance that had been their prime professional as well as legal duty but somehow are not inclined to penalize them harshly in wider prospective of the situation and thus ORDER for the one moderate compensation in the fairness and righteousness of the matter, in hand.”

Filing the consumer complaint, the patient sought Rs 5 lakh compensation (including Rs 1.44 lakh paid as medical and hospitalization fees) alleging that the treating doctor and hospital subjected him to one immature/hasty Coronary Percutaneous Old Balloon Angioplasty (POBA) procedure that had to be abandoned incomplete causing much pain discomfort, worry and monetary loss to him and his family members.

The matter goes back to 2020 when the patient was admitted to IVY Hospital Super Specialty Health Care, Hoshiarpur, with chest pain and seating etc where the attending specialist Dr Handa prescribed an immediate Percutaneous Old Balloon Angioplasty (POBA) procedure. The patient was informed that the procedure would cost approximately Rs 1.5 lakh. Accordingly, the procedure was conducted.

However, soon after the procedure, the patient complained of severe chest pain and the doctor declared that the patient required the lifesaving stent-pacing in the blocked artery carrying an additional cost of Rs.3 lakh. However, the family of the patient disagreed and sought discharge from the hospital for a second opinion. They were made to pay Rs 1,44,000 at the hospital.

It was submitted that the patient had to undergo many further medical treatments costing Rs 2 lakh to recover and regain normalcy. Therefore, the patient filed a consumer complaint and sought relief.

On the other hand, the doctor and the hospital denied all the allegations. The doctor submitted that the attending relatives of the complainant had consented to angioplasty in writing which appeared as the medical urgency/ necessity qua the clinical reports and the symbolic signs of ailment.

However, the doctor admitted that the Angioplasty procedure could not be done successfully on account of the affected condition of the patient’s arteries/veins etc. Therefore, the doctor advised for CABG on the next day. However, the patient opted for discharge and LAMA was issued.

The doctor affirmed that it was the patient’s health status and the deteriorated conditions of his related arteries/veins that failed the Angioplasty procedure and not any sort of negligence or deficiency in service on their part.

Similarly, the hospital also denied all allegations. It submitted that the treating doctor has been one of the best Cardiologists in the country and the allegations labelled against him were false.

While considering the matter, the consumer court thoroughly examined the available documents/evidence on the records and noted that the main issue of dispute was over the allegation that the patient was mechanically subjected to the Angioplasty Procedures that had to be admittedly abandoned in between on account of technical non-suitability to the subject of narrowing down of the arteries/veins due to the advanced age of the patient (66 years) and cholesterol/calcium deposits etc. Therefore, the necessity for CABG surgery arose.

At this outset, the Commission observed,

“We find no evidence on the records so as to say in medical terms/ prove that it’s the one failed attempt to Angioplasty that necessitates Bye-Pass Heart Surgery that could have been first opted by the experienced (as claimed in the written-reply) cardiologist so as to rule out the avoidable procedure associated with pain and expense. We take notice of the argument as put forth by the learned counsel for the complainant that even if we somewhat believe the defense for arguments sake that there’s been no stark negligence/ deficiency in service on the OP’s part it stays on records that the OP had not been vigilant as was desired of him while performing/ deciding of the human-life saving procedure.”

Further, the Commission noted that an amount of Rs 1.44 lakh was deposited at the time of LAMA discharge in the face of an admittedly unsuccessful attempt at Angioplasty.

Apart from this, the consumer court also noted that the doctor and the hospital failed to rebut these allegations with evidence on record and opined that it “…places them on the receiving end of the statute. Also, the complainant has not produced complete records of his stay at the OP2 Hospital but that was presumably not made available to him and that was neither produced by the OP who have failed even to rebut some of these allegations through cogent evidence.”

Holding the hospital and the doctor liable, the Commission observed,

“Finally, in the matter pertaining to the present complaint and in the light of the all above, we conclude/ deduce that the OP 1 and the OP2 have caused an unintentional loss to the complainant through lack of care, caution and vigilance that had been their prime professional as well as legal duty but somehow are not inclined to penalize them harshly in wider prospective of the situation and thus ORDER for the one moderate compensation in the fairness and righteousness of the matter, in hand.”

Therefore, the District Consumer Court granted the Complainant with Rs 2 lakh lump sum as cost and compensation and ordered, “Lastly, we are of the considered opinion that the complainant deserves to be moderately compensated and thus we partly allow this complaint and ORDER the OP1 Doctor & the OP2 Hospital to pay an amount of Rs.2.0 Lac, in lump-sum as cost and compensation with interest @ 9% PA with effect from the date of filing of the complaint till realization within 45 days of receipt of the copy of these orders, otherwise the entire awarded amount shall attract additional interest @ 6% PA form the date of the orders till.”

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/punjab-dcdrc-compensation-233969.pdf

Also Read: ENT surgeon, Hospital directed to pay compensation for vision loss after nasal surgery

Powered by WPeMatico

USFDA delays decision on Eli Lilly Alzheimer’s drug Donanemab

United States: The U.S. Food and Drug Administration has delayed its decision on Eli Lilly’s experimental treatment for early Alzheimer’s disease and will hold a meeting of outside experts to discuss its safety and efficacy, the company said.

The FDA’s decision came as a surprise to company officials and many Alzheimer’s experts, who had expected a full approval for Lilly’s drug donanemab this month based on clinical trial data last year that showed the treatment was safe and effective.
No date has been set for the advisory committee meeting, but it could be several months before it is held. 
This marks the second delay for the eagerly anticipated treatment by the FDA after it declined to grant accelerated approval for the medicine a year ago.
Drugs like donanemab, which slow disease progression in early-stage patients, represent a new era in the treatment of Alzheimer’s, after three decades of failed attempts to fight the fatal disease that affects more than 6 million Americans, according to the Alzheimer’s Association.
“This was definitely unexpected,” Anne White, president of Lilly Neuroscience, said in an interview, adding that the news came very late in the review process and the company had been ready to launch the drug.
White said the FDA wants the expert panel to discuss some of the unique aspects of the clinical trial used in its request for a traditional FDA approval, including issues around efficacy and safety.
The FDA had conducted advisory committee meetings before approving Eisai and Biogen’s Leqembi, which received standard authorization last year and works in a similar manner. The agency declined to comment on its decision.
Given by infusion once a month, donanemab is designed to clear a toxic Alzheimer’s-linked protein called beta amyloid from the brain.
The treatment slowed progression of memory and thinking problems by 22% to 29% overall in a large clinical trial, roughly comparable to the 27% slowing seen with Leqembi.
In patients with low-to-medium levels of a second Alzheimer’s related protein called tau, the drug slowed disease progression by 35.1% compared with placebo.
Brain swelling, a known side effect of this type of drug, occurred in 24% of the donanemab treatment group, while brain bleeding occurred in 31% of the donanemab group and about 14% of the placebo group.
In the trial, participants could stop treatment as soon as brain imaging showed that the drug had cleared the amyloid.
Lilly’s White said that design, as well as the use of tau to group patients and assess the drug’s benefit, were likely to be discussed at the advisory meeting.

‘EXTRA CAUTION’

Experts said the drug’s association with brain swelling and bleeding could be at issue. Three people on the treatment in the company’s trial died.

Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital in St. Louis, had expected the drug to be approved this month. He pointed to donanemab’s higher rates of serious side effects compared with Leqembi as one possible reason’s for the FDA’s “extra caution.”
Allowing patients to stop treatment once the drug has done its job of removing amyloid could also be a factor, but Musiek sees that as an advantage over Leqembi, which is given twice a month indefinitely.
Dr. Mary Sano, director of the Alzheimer’s Disease Research Center at Mount Sinai in New York, suggested that the FDA may be struggling with how to manage patients who stop the treatment and later need to restart it, which could expose them to additional side effects.
“These are not drugs without adverse events. They’re not drugs that are inexpensive, and they’re time-consuming for the patient. You really want to make sure that they’re value-added,” she said.
Leqembi costs $26,500 per year for an average patient.
Indianapolis-based Lilly said there was no change to its 2024 financial forecast.
Analysts on average expect donanemab sales of $189.6 million in 2024, rising to $837 million next year, according to LSEG data. In February, Lilly forecast 2024 revenue of $40.4 billion to $41.6 billion, driven largely by its weight-loss and diabetes drugs.
BMO Capital Markets analyst Evan Seigerman said he believes Lilly’s drug will ultimately prevail. “The data is good. It’s relatively safe and checks all the boxes.”

Read also: Eli Lilly finds bacteria, other impurities in Mounjaro, Zepbound knockoffs

Powered by WPeMatico

Synokem gets CDSCO Panel Nod To Study FDC Dapagliflozin plus Sacubitril plus Valsartan

New Delhi: The drug major Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the bioequivalence (BE) study of the fixed-dose combination (FDC) Dapagliflozin Propanediol Monohydrate plus Sacubitril plus Valsartan Sodium Salt Film Coated Tablets.

This came after Synokem Pharmaceutical presented its proposal and the BE study protocol before the committee.

Dapagliflozin works by increasing the removal of sugar by your kidneys. Dapagliflozin is also used to treat kidney disease and heart failure. It helps to lower the risk of death from heart disease and reduces the need to go to a doctor or hospital to treat heart failure.

The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.

Sacubitril is a neprilysin inhibitor used in combination with valsartan as an adjunct to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

Sacubitril acts by preventing the breakdown of endogenous vasoactive peptides, including natriuretic peptides (ANP, BNP, and CNP), thereby limiting myocardial cell death.

Valsartan is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten. Valsartan relaxes the blood vessels and lowers blood pressure

At the recent SEC meeting for Cardiovascular held on 20th February 2024, the expert panel reviewed the proposal presented by drug maker Synokem to conduct the BE study of the FDC Dapagliflozin Propanediol Monohydrate plus Sacubitril plus Valsartan Sodium Salt Film Coated Tablets.

After detailed deliberation, the committee recommended the grant of permission to conduct the BE Study.

Accordingly, the expert panel suggested that the firm should submit the BE study report for review by the committee and for taking further decisions on the Phase III clinical trial protocol.

Also Read:Justify bioequivalent data: CDSCO Panel Tells Sun Pharma on Mirabegron Extended-release Tablets

Powered by WPeMatico

Maharashtra to get 10 new medical colleges soon, 1000 MBBS seats to be added

Maharashtra- 1,000 MBBS seats will be added to 10 new medical colleges in Maharashtra from the forthcoming academic year. Recently, the Maharashtra government has sanctioned 2,440 teaching posts and 2,040 non-teaching posts for 10 new medical colleges in the state. Additionally, the patient capacity of the state’s public hospitals will increase by 4,300 beds, which will include 430 beds in each of these 10 new colleges.

In July 2023, the Maharashtra government approved the establishment of 10 additional government medical colleges in 10 districts at a cost of ₹4,366 crore. These 10 new medical colleges are decided to be set up in Gadchiroli, Bhandara, Buldhana, Washim, Wardha, Amravati, Jalna, Hingoli, Thane, and Palghar districts of Maharashtra. Along with this, the government has also approved 448 posts for each new medical college at an estimated cost of Rs 312.20 crore.

Also Read: Maharashtra Medical Council slaps show-cause notice on doctor accused of not performing 1 of 3 surgeries

According to the Hindustan Times, a government resolution (GR) has stated “As per norms of the World Health Organisation (WHO) mandating a 1:1000 doctor-to-population ratio, the state government has decided to address the shortage of doctors in the state and ensure timely access to healthcare services by establishing ten new colleges”.

GR further added “The state government is planning to open these colleges from the coming academic year,” said a senior official from the directorate of medical education and research. “This is the first step towards National Medical Council (NMC) approval”.

Also Read: Maharashtra soon to get new GMC in Jalna with 100 MBBS seats, 448 posts approved

On the other hand, Sudha Shenoy, a medical admission counsellor also said “We have been waiting for new seats for a very long time. While the government will create teaching and non-teaching staff posts, no one is addressing infrastructural facilities which must be required for the NMC approval. If the government is planning to provide new seats from the current academic year, they need to act fast, otherwise, it will remain on paper like last year”.

Before approving 10 medical colleges, the government had proposed the establishment of 12 medical colleges in the same year during the presentation of the state budget.

Also Read: Maharashtra: Eight Government Medical Colleges to soon offer free IVF treatment

Powered by WPeMatico

Govt to complete work on medical colleges on priority: Rajasthan CM Bhajanlal Sharma

Jaipur: Rajasthan Chief Minister Bhajanlal Sharma said his government is working to expand and strengthen health services in the state. 

The government will get the work of all approved government medical colleges completed on priority to ensure people can access quality facilities in their own districts, he said while addressing virtually a foundation stone laying ceremony of a private medical college here.

During the tenure of the previous government, even after the approval of 15 medical colleges, the pace of work remained slow and the amount received from the Centre could not be fully utilised, the chief minister said, according to an official statement.

Also Read:50-year-old brain dead man donates organs, saves three lives in Rajasthan

The Congress was in power in the state and was defeated by the BJP in the assembly elections last year.

In order to realise the concept of “Arogya Rajasthan”, the state government has included in its budget the Chief Minister Ayushman Arogya Yojana, Sharma said

He said that after 2014, there have been revolutionary changes in the field of medical education in the country and the number of medical colleges has increased to 706.

Referring to the Centre’s Swadesh Darshan and Prasad Yojana, Sharma at another event said the Rajasthan government has made a provision of Rs 300 crore in the coming year for the development works of 20 temples and places of worship in the state.

He said that the previous Congress government only believed in making announcements, it had no plan to implement these on the ground. But now tourism-related announcements will be completed soon, Sharma said.

Medical Dilaogues team had earlier reported that the Rajasthan Medical and Health Department extended up to June 2024 the service period of 735 doctors working on an urgent temporary basis (UTB).

Also Read:735 doctors get extension in Rajasthan amid COVID surge

Powered by WPeMatico